Gauer S, Schulze-Lohoff E, Schleicher E, Sterzel R B
Medizinische Klinik IV, Universität Erlangen-Nürnberg, Germany.
Eur J Cell Biol. 1996 Jul;70(3):233-42.
To explore whether the heparan sulfate proteoglycan, periecan, may act as a regulator of glomerular cell behavior, we examined the effects of perlecan on adhesive properties of rat and human mesangial cells in culture. We observed that mesangial cells did not adhere to purified perlecan. Mesangial cell adhesion to fibronectin, but not to laminin, was inhibited when perlecan was present in the substratum, reaching complete inhibition at 20 micrograms/ml perlecan. Similarly, perlecan reduced mesangial cell adhesion to the 120 kDa fragment of fibronectin and to bovine serum albumin-coupled RGD peptides both lacking the fibronectin heparin-binding domains, indicating that the inhibitory effect of perlecan does not require interaction of its heparan sulfate chains with fibronectin. The core protein of perlecan seems to be relevant, since perlecan retained most of its anti-adhesive potency after total deglycosylation. It is unlikely that perlecan causes steric inhibition of the cell binding sites of fibronectin by direct binding, since the 120 kDa fragment of fibronectin which includes the cell binding site, did not bind to intact perlecan. In the presence of submaximal inhibitory concentrations of perlecan, soluble RGD peptides (100 micrograms/ml), by themselves without effect, completely inhibited cell adhesion to fibronectin. Using immunocytochemistry, we examined the effects of perlecan on the organization of fibronectin-specific, RGD-dependent beta 1 integrins in focal contacts. When perlecan was added to the substratum, human mesangial cells adhered to fibronectin only in the presence of collagen I. Under these conditions, perlecan did not significantly alter the organization of alpha 5 beta 1 integrin into focal contacts of mesangial cells which adhered to a substratum composed of collagen I plus fibronectin. These data suggest that perlecan exerts its anti-adhesive effects on mesangial cells via a core protein-dependent mechanism which reduces the avidity of the fibronectin receptor. The resulting avidity level is too low for mediating cell binding but sufficient to induce integrin organization into focal contacts.
为了探究硫酸乙酰肝素蛋白聚糖(基底膜聚糖)是否可作为肾小球细胞行为的调节因子,我们检测了基底膜聚糖对培养的大鼠和人系膜细胞黏附特性的影响。我们观察到系膜细胞不黏附于纯化的基底膜聚糖。当基底膜聚糖存在于底物中时,系膜细胞对纤连蛋白的黏附受到抑制,但对层粘连蛋白的黏附不受影响,在基底膜聚糖浓度为20微克/毫升时达到完全抑制。同样,基底膜聚糖降低了系膜细胞对纤连蛋白120 kDa片段以及对缺乏纤连蛋白肝素结合域的牛血清白蛋白偶联RGD肽的黏附,这表明基底膜聚糖的抑制作用并不需要其硫酸乙酰肝素链与纤连蛋白相互作用。基底膜聚糖的核心蛋白似乎与之相关,因为完全去糖基化后基底膜聚糖仍保留了大部分抗黏附能力。基底膜聚糖不太可能通过直接结合对纤连蛋白的细胞结合位点产生空间位阻抑制,因为包含细胞结合位点的纤连蛋白120 kDa片段并不与完整的基底膜聚糖结合。在存在次最大抑制浓度的基底膜聚糖时,本身无作用的可溶性RGD肽(100微克/毫升)完全抑制了细胞对纤连蛋白的黏附。我们使用免疫细胞化学方法检测了基底膜聚糖对黏着斑中纤连蛋白特异性、RGD依赖性β1整合素组织的影响。当将基底膜聚糖添加到底物中时,人系膜细胞仅在存在I型胶原的情况下黏附于纤连蛋白。在这些条件下,基底膜聚糖并未显著改变α5β1整合素在黏附于由I型胶原加纤连蛋白组成的底物的系膜细胞黏着斑中的组织。这些数据表明,基底膜聚糖通过一种依赖核心蛋白的机制对系膜细胞发挥抗黏附作用,该机制降低了纤连蛋白受体的亲和力。产生的亲和力水平过低,无法介导细胞结合,但足以诱导整合素组织形成黏着斑。